10-Q · May 12, 2026
Imunon, Inc. reported a net loss of $4.3 million for Q1 2026, slightly more than the $4.1 million loss in Q1 2025. With no revenue generated during the quarter, the company's cash position stood at $4.8 million, raising…
Earnings analysis · 10-Q
IMNN earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The available 10-Q excerpt does not include the detailed statements of operations, balance sheet, cash flow statement, segment disclosures, or MD&A needed to assess revenue, margins, liquidity, working capital, and…
Read full summary
The available 10-Q excerpt does not include the detailed statements of operations, balance sheet, cash flow statement, segment disclosures, or MD&A needed to assess revenue, margins, liquidity, working capital, and cash-burn trends. Reported Q2 2026 EPS was negative $0.54 based on the supplied earnings information. The filing identifies no material risk-factor changes from the 2025 Form 10-K, while June 2, 2026 secured financing arrangements and ongoing clinical-stage funding needs remain material considerations.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.54
What stood out
-
Limited equity compensation issuance
The company issued 49,135 shares of common stock to employees and directors during the quarter ended June 30, 2026 under compensatory arrangements.
-
Disclosure controls deemed effective
Management concluded that disclosure controls were effective at the reasonable assurance level as of June 30, 2026.
-
No material control changes
The filing reports no changes in internal control over financial reporting during the period that materially affected, or were reasonably likely to materially affect, controls.
What to watch
-
Inherent control limitations
The company states that its disclosure controls and internal controls cannot provide absolute assurance, and that errors, fraud, collusion, or management override may not be detected.
-
Ongoing 2025 10-K risk exposure
The filing incorporates the risks from the 2025 Form 10-K and states there have been no material changes; additional unknown or currently immaterial risks could still adversely affect the business.
-
Secured debt financing reliance
The company has entered into secured financing arrangements dated June 2, 2026, including Secured Promissory Notes A-1 and B, indicating continued reliance on debt financing.
Management's outlook
No quantitative revenue or EPS guidance is provided in the available 10-Q text. The filing states that there were no material changes to the risk factors disclosed in the 2025 Form 10-K.
Earlier filings 4
10-K · March 31, 2026
Imunon reports compelling Phase II (OVATION 2) clinical results for IMNN-001 showing meaningful overall survival and PFS improvements, while remaining a pre‑revenue clinical-stage company with ongoing Phase 3…
10-Q · November 13, 2025
Imunon reported an improved operating and earnings trend in Q3 2025 with a net loss of $3,429,124 (Q3 EPS $(1.16)) versus a net loss of $4,845,475 (EPS $(3.76)) in Q3 2024, driven by materially lower R&D and overall…
10-Q · August 5, 2025
Imunon reported a materially narrower quarterly loss: net loss of $2,740,559 (EPS $(2.15)) for Q2 2025 versus $4,788,017 (EPS $(7.64)) in Q2 2024, driven by sharply lower operating expenses. Management reduced R&D and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.